These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18474531)

  • 1. Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity.
    Lobato MN; Jereb JA; Starke JR
    Pediatrics; 2008 Jun; 121(6):e1732-3. PubMed ID: 18474531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
    Salpeter SR; Sanders GD; Salpeter EE; Owens DK
    Ann Intern Med; 1997 Dec; 127(12):1051-61. PubMed ID: 9412307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isoniazid hepatotoxicity after orthotopic liver transplantation.
    Schluger LK; Sheiner PA; Jonas M; Guarrera JV; Fiel IM; Meyers B; Berk PD
    Mt Sinai J Med; 1996; 63(5-6):364-9. PubMed ID: 8898542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection.
    Aziz H; Shubair M; Debari VA; Ismail M; Khan MA
    Curr Med Res Opin; 2006 Jan; 22(1):217-21. PubMed ID: 16393447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
    Fountain FF; Tolley E; Chrisman CR; Self TH
    Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of chronic hepatitis in isoniazid hepatotoxicity during treatment for latent tuberculosis infection.
    Bliven EE; Podewils LJ
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1054-60. PubMed ID: 19723392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
    Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
    Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatotoxicity caused by isoniazid or by paracetamol].
    Andrade RJ; Lucena MI; Melgarejo F; García-Escaño MD
    Gastroenterol Hepatol; 1998; 21(6):314-5. PubMed ID: 9711017
    [No Abstract]   [Full Text] [Related]  

  • 9. Isoniazid-induced crescentic glomerulonephritis in a child with a positive tuberculin skin test.
    Brik R; Magen D; Ben-Yzhak O; Grin J
    Am J Nephrol; 1998; 18(5):430-2. PubMed ID: 9730569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
    Nolan CM; Goldberg SV; Buskin SE
    JAMA; 1999 Mar; 281(11):1014-8. PubMed ID: 10086436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An unusual recurrence of antitubercular drug induced hepatotoxicity in a child.
    Bhatia S; Tullu MS; Kannan S; Gogtay NJ; Thatte UM; Lahiri KR
    J Postgrad Med; 2011; 57(2):147-52. PubMed ID: 21654145
    [No Abstract]   [Full Text] [Related]  

  • 13. Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection.
    Devrim İ; Devrim F; Bayram N; Aktürk H; Aksay A; Can D; Apa H
    Minerva Pediatr (Torino); 2021 Apr; 73(2):184-187. PubMed ID: 26377643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
    Schreiber J; Zissel G; Greinert U; Schlaak M; Müller-Quernheim J
    Eur J Med Res; 1999 Feb; 4(2):67-71. PubMed ID: 10066642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoniazid-related hepatitis.
    Vasudeva R; Woods B
    Dig Dis; 1997; 15(6):357-67. PubMed ID: 9439900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity.
    Hayashi PH; Fontana RJ; Chalasani NP; Stolz AA; Talwalkar JA; Navarro VJ; Lee WM; Davern TJ; Kleiner DE; Gu J; Hoofnagle JH;
    Clin Gastroenterol Hepatol; 2015 Sep; 13(9):1676-82.e1. PubMed ID: 25724701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged isoniazid prevention in HIV-positive children: hepatotoxicity is not a major problem.
    Loddenkemper R; Diel R
    Int J Tuberc Lung Dis; 2013 Jan; 17(1):1. PubMed ID: 23231996
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of isoniazid-related hepatotoxicity during chemoprophylaxis.
    Stuart RL; Grayson ML
    Aust N Z J Med; 1999 Jun; 29(3):362-7. PubMed ID: 10868500
    [No Abstract]   [Full Text] [Related]  

  • 19. [Severe hepatitis induced by chemotherapy with antitubercular agents in childhood. 2 cases].
    Chapoy P; Ferracci JP; Mattei JF; Granjon B; Louchet E
    Pediatrie; 1978; 3(7):637-45. PubMed ID: 740454
    [No Abstract]   [Full Text] [Related]  

  • 20. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
    Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
    Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.